Bad news for Novo Nordisk (NVO -17.83%) Friday was good news for Eli Lilly (LLY 1.35%) and Viking Therapeutics (VKTX 1.83%), its two main rivals in the field of weight loss drugs. This morning, Novo reported headline results from its phase 3 trial of a new weight loss drug, CagriSema, and while…
Continue reading...
Continue reading...